Gufic Biosciences Ltd

Gufic Biosciences Ltd maintains a capital structure with a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.61, suggesting it can cover its short-term obligations with its current assets. However, the company's cash and equivalents amount to INR 157.23 million, which is significantly lower than its long-term debt of INR 3,361.95 million, resulting in a negative net cash position. In terms of profitability, Gufic Biosciences Ltd reports a return on equity (ROE) of 11.59% and a return on assets (ROA) of 5.96%. These figures are to be compared against the industry's preferred metrics, which typically emphasize ROE and ROA as key indicators of financial performance. The company's ROE is relatively strong, suggesting efficient use of equity capital, while the ROA indicates moderate asset utilization efficiency. The company's revenue is derived from a diverse range of pharmaceutical products, including Criti Care, Criticare Life, Ferticare, Spark, Herbal, and Aesthaderm, as well as personal care and active pharmaceutical ingredients (APIs). The geographic exposure is primarily concentrated in India, with no significant international revenue disclosed. The company's product portfolio is segmented into various therapeutic areas, with no single segment accounting for a disproportionately large share of revenue. Gufic Biosciences Ltd's growth trajectory is reflected in its financial performance. The company's revenue for the latest period is INR 8,198.06 million, with a gross profit of INR 4,046.83 million. The operating income is INR 1,173.33 million, and the net income is INR 696.50 million. The company's capital expenditure is negative INR 755.26 million, indicating a reduction in capital spending. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's operating cash flow of INR 1,225.68 million and free cash flow of INR 141.79 million suggest a stable cash flow position. The risk assessment for Gufic Biosciences Ltd highlights a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which could impact its ability to meet long-term obligations. The dilution potential is low, as indicated by the low dilution risk score, and there are no significant adjustments applied to the valuation metrics. Recent events and filings for Gufic Biosciences Ltd are not explicitly detailed in the provided data. However, the company's financial performance and risk profile suggest a stable but cautious outlook. The company's operating cash flow and free cash flow indicate a positive cash flow position, which is a positive sign for its financial health. The company's capital expenditure is negative, which may indicate a strategic decision to reduce capital spending or a decrease in investment in new projects.